Key facts
- It has raised $790K across 1 recorded rounds; the latest was Seed Round ($785K) in Feb 2024.
- Notable investors include Endless Frontier Labs, Harvard Innovation Launch Lab, Phoenix Investment Club (San Francisco), Pillar VC, MassBio — 10 tracked in total.
- Modulate Bio has filed 2 Form Ds with the SEC since 2024, most recently Jun 2025 ($660K sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Modulate Bio
Funding rounds
1 roundsAbout Modulate Bio
Provider of allosteric small-molecule therapies intended to treat neurological disorders, namely essential tremor, epilepsy, and anxiety. The company is addressing on-target toxicology at the GABA-A receptor by developing controlled GABA-A positive allosteric modulators and leveraging a proprietary computational model and an advanced in vitro screening funnel, thereby enabling patients to receive an effective and safe therapy for essential tremor.
- Sector
- Healthcare
- HQ
- Allston, MA, United States
- Founded
- 2023
- Employees
- 4
- Website
- modulatebio.com/
- Ownership
- Privately Held (backing)
Modulate Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Modulate Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Modulate Bio in its N-PORT filings yet. We sweep new filings monthly.